AB0536 Tocilizumab offers clinical and ultrasonographic improvement in rheumatoid arthritis patients. Results of a 6 months follow-up study
Background Tocilizumab (TCZ) is a humanized anti-interleukin 6 (anti-IL 6) receptor antibody that has been demonstrated in previous clinical trials to improve rheumatoid arthritis (RA) and prevent radiographic progression. Musculoskeletal ultrasonography (MSUS) has increasingly been used as outcome...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.669-669 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 669 |
|---|---|
| container_issue | Suppl 3 |
| container_start_page | 669 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 71 |
| creator | Bouaddi, I. Rkain, H. Aktaou, S. Raissouni, H. Traki, L. Bouazzaoui, L. Benchakroun, B. Benbrahim, L. Rostom, S. Allali, F. Bahiri, R. Amine, B. Benbouazza, K. Hajjaj-Hassouni, N. |
| description | Background Tocilizumab (TCZ) is a humanized anti-interleukin 6 (anti-IL 6) receptor antibody that has been demonstrated in previous clinical trials to improve rheumatoid arthritis (RA) and prevent radiographic progression. Musculoskeletal ultrasonography (MSUS) has increasingly been used as outcome measures in clinical trials of RA. Thus, we aimed to evaluate clinical and ultrasonographic (US) progression in RA patients treated with TCZ. Methods Twenty two consecutive patients, affected by RA [19 females, median age of 41 years (35,50), median disease duration of 72 months (36,171)] who were non-responders or partial responders to DMARDs therapy were commenced on Tocilizumab. The patients underwent clinical, laboratory, and assessment at baseline and after 6 months. The Disease Activity Score in 28 joints (DAS28) was recorded at inclusion and after a 6 months of therapy.The German ultrasound score included the following joints of the clinically dominant hand and foot: wrist, second and third metacarpophalangeal and proximal interphalangeal, and second and fifth metatarsophalangeal joints. Synovitis and synovial vascularity were scored semiquantitatively (grade 0–3) by gray-scale (GS) and power Doppler (PD) ultrasound. Clinical remission after 6 months of treatment was defined when DAS 28 was |
| doi_str_mv | 10.1136/annrheumdis-2012-eular.536 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777973710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008650861</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1630-939d6982df74cbe8442a226e841035960d513874d950fe91b152fcce227aca9e3</originalsourceid><addsrcrecordid>eNqVkM1u1DAUhS0EEsPAO1iwzuCfxI7ZlaG0SFWRqkIlNtaN4zAeEjvYDrSs2LDkJXkS3A5CbFnZvj7nu_cehJ5SsqGUi-fgfdzZZepdqhihrLLLCHHTcHEPrWgt2lIV5D5aEUJ4VSshH6JHKe3Lk7S0XaGfRy9JUf_6_uMyGDe6b8sEHQ7DYGPCZnTeGRgx-B4vY46Qgg8fI8w7Z7Cb5hi-2Mn6jJ3Hd3NADq7HEPMuuuwSniG78p82-MKmQkgFjQELPAWfdwkPYRzD12qZccpLf_MYPRhgTPbJn3ON3r0-vtyeVmdvT95sj86qjgpOKsVVL1TL-kHWprNtXTNgTJQLJbxRgvQN5a2se9WQwSra0YYNxljGJBhQlq_RswO3bPB5sSnrfViiLy01lVIqyWUhrdGLg8rEkFK0g56jmyDeaEr0bfz6n_j1bfz6Ln5dAi3m6mB2Kdvrv06In7Qo-Eafv9_qq6tXp_V5_UFfFH1z0HfT_n_6_AbNP6Mo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777973710</pqid></control><display><type>article</type><title>AB0536 Tocilizumab offers clinical and ultrasonographic improvement in rheumatoid arthritis patients. Results of a 6 months follow-up study</title><source>BMJ Journals - NESLi2</source><creator>Bouaddi, I. ; Rkain, H. ; Aktaou, S. ; Raissouni, H. ; Traki, L. ; Bouazzaoui, L. ; Benchakroun, B. ; Benbrahim, L. ; Rostom, S. ; Allali, F. ; Bahiri, R. ; Amine, B. ; Benbouazza, K. ; Hajjaj-Hassouni, N.</creator><creatorcontrib>Bouaddi, I. ; Rkain, H. ; Aktaou, S. ; Raissouni, H. ; Traki, L. ; Bouazzaoui, L. ; Benchakroun, B. ; Benbrahim, L. ; Rostom, S. ; Allali, F. ; Bahiri, R. ; Amine, B. ; Benbouazza, K. ; Hajjaj-Hassouni, N.</creatorcontrib><description>Background Tocilizumab (TCZ) is a humanized anti-interleukin 6 (anti-IL 6) receptor antibody that has been demonstrated in previous clinical trials to improve rheumatoid arthritis (RA) and prevent radiographic progression. Musculoskeletal ultrasonography (MSUS) has increasingly been used as outcome measures in clinical trials of RA. Thus, we aimed to evaluate clinical and ultrasonographic (US) progression in RA patients treated with TCZ. Methods Twenty two consecutive patients, affected by RA [19 females, median age of 41 years (35,50), median disease duration of 72 months (36,171)] who were non-responders or partial responders to DMARDs therapy were commenced on Tocilizumab. The patients underwent clinical, laboratory, and assessment at baseline and after 6 months. The Disease Activity Score in 28 joints (DAS28) was recorded at inclusion and after a 6 months of therapy.The German ultrasound score included the following joints of the clinically dominant hand and foot: wrist, second and third metacarpophalangeal and proximal interphalangeal, and second and fifth metatarsophalangeal joints. Synovitis and synovial vascularity were scored semiquantitatively (grade 0–3) by gray-scale (GS) and power Doppler (PD) ultrasound. Clinical remission after 6 months of treatment was defined when DAS 28 was <2.6. Results At baseline, the median DAS28 score was 5.2 (4.4, 6.2) and the synovitis scores were 9.5 (6.7, 15) in GS ultrasound and 2.5 (0,7.2) in PD ultrasound. After 6 months of therapy, the DAS28 significantly decreased to 1.6 (0.8,2.4); p<0.001 and the GS and PD ultrasound scores significantly decreased to respectively 5 (4,6); p=0.001 and to 0.5 (0,1.7); p=0.04. Remission at 6 months was noted in 70% of patients. Conclusions This study indicates good evolution of RA patients under TCZ on basis on clinical and ultrasonographic findings. These results should be verified by further studies. Disclosure of Interest None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2012-eular.536</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.669-669</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/71/Suppl_3/669.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/71/Suppl_3/669.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Bouaddi, I.</creatorcontrib><creatorcontrib>Rkain, H.</creatorcontrib><creatorcontrib>Aktaou, S.</creatorcontrib><creatorcontrib>Raissouni, H.</creatorcontrib><creatorcontrib>Traki, L.</creatorcontrib><creatorcontrib>Bouazzaoui, L.</creatorcontrib><creatorcontrib>Benchakroun, B.</creatorcontrib><creatorcontrib>Benbrahim, L.</creatorcontrib><creatorcontrib>Rostom, S.</creatorcontrib><creatorcontrib>Allali, F.</creatorcontrib><creatorcontrib>Bahiri, R.</creatorcontrib><creatorcontrib>Amine, B.</creatorcontrib><creatorcontrib>Benbouazza, K.</creatorcontrib><creatorcontrib>Hajjaj-Hassouni, N.</creatorcontrib><title>AB0536 Tocilizumab offers clinical and ultrasonographic improvement in rheumatoid arthritis patients. Results of a 6 months follow-up study</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background Tocilizumab (TCZ) is a humanized anti-interleukin 6 (anti-IL 6) receptor antibody that has been demonstrated in previous clinical trials to improve rheumatoid arthritis (RA) and prevent radiographic progression. Musculoskeletal ultrasonography (MSUS) has increasingly been used as outcome measures in clinical trials of RA. Thus, we aimed to evaluate clinical and ultrasonographic (US) progression in RA patients treated with TCZ. Methods Twenty two consecutive patients, affected by RA [19 females, median age of 41 years (35,50), median disease duration of 72 months (36,171)] who were non-responders or partial responders to DMARDs therapy were commenced on Tocilizumab. The patients underwent clinical, laboratory, and assessment at baseline and after 6 months. The Disease Activity Score in 28 joints (DAS28) was recorded at inclusion and after a 6 months of therapy.The German ultrasound score included the following joints of the clinically dominant hand and foot: wrist, second and third metacarpophalangeal and proximal interphalangeal, and second and fifth metatarsophalangeal joints. Synovitis and synovial vascularity were scored semiquantitatively (grade 0–3) by gray-scale (GS) and power Doppler (PD) ultrasound. Clinical remission after 6 months of treatment was defined when DAS 28 was <2.6. Results At baseline, the median DAS28 score was 5.2 (4.4, 6.2) and the synovitis scores were 9.5 (6.7, 15) in GS ultrasound and 2.5 (0,7.2) in PD ultrasound. After 6 months of therapy, the DAS28 significantly decreased to 1.6 (0.8,2.4); p<0.001 and the GS and PD ultrasound scores significantly decreased to respectively 5 (4,6); p=0.001 and to 0.5 (0,1.7); p=0.04. Remission at 6 months was noted in 70% of patients. Conclusions This study indicates good evolution of RA patients under TCZ on basis on clinical and ultrasonographic findings. These results should be verified by further studies. Disclosure of Interest None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkM1u1DAUhS0EEsPAO1iwzuCfxI7ZlaG0SFWRqkIlNtaN4zAeEjvYDrSs2LDkJXkS3A5CbFnZvj7nu_cehJ5SsqGUi-fgfdzZZepdqhihrLLLCHHTcHEPrWgt2lIV5D5aEUJ4VSshH6JHKe3Lk7S0XaGfRy9JUf_6_uMyGDe6b8sEHQ7DYGPCZnTeGRgx-B4vY46Qgg8fI8w7Z7Cb5hi-2Mn6jJ3Hd3NADq7HEPMuuuwSniG78p82-MKmQkgFjQELPAWfdwkPYRzD12qZccpLf_MYPRhgTPbJn3ON3r0-vtyeVmdvT95sj86qjgpOKsVVL1TL-kHWprNtXTNgTJQLJbxRgvQN5a2se9WQwSra0YYNxljGJBhQlq_RswO3bPB5sSnrfViiLy01lVIqyWUhrdGLg8rEkFK0g56jmyDeaEr0bfz6n_j1bfz6Ln5dAi3m6mB2Kdvrv06In7Qo-Eafv9_qq6tXp_V5_UFfFH1z0HfT_n_6_AbNP6Mo</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Bouaddi, I.</creator><creator>Rkain, H.</creator><creator>Aktaou, S.</creator><creator>Raissouni, H.</creator><creator>Traki, L.</creator><creator>Bouazzaoui, L.</creator><creator>Benchakroun, B.</creator><creator>Benbrahim, L.</creator><creator>Rostom, S.</creator><creator>Allali, F.</creator><creator>Bahiri, R.</creator><creator>Amine, B.</creator><creator>Benbouazza, K.</creator><creator>Hajjaj-Hassouni, N.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>AB0536 Tocilizumab offers clinical and ultrasonographic improvement in rheumatoid arthritis patients. Results of a 6 months follow-up study</title><author>Bouaddi, I. ; Rkain, H. ; Aktaou, S. ; Raissouni, H. ; Traki, L. ; Bouazzaoui, L. ; Benchakroun, B. ; Benbrahim, L. ; Rostom, S. ; Allali, F. ; Bahiri, R. ; Amine, B. ; Benbouazza, K. ; Hajjaj-Hassouni, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1630-939d6982df74cbe8442a226e841035960d513874d950fe91b152fcce227aca9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bouaddi, I.</creatorcontrib><creatorcontrib>Rkain, H.</creatorcontrib><creatorcontrib>Aktaou, S.</creatorcontrib><creatorcontrib>Raissouni, H.</creatorcontrib><creatorcontrib>Traki, L.</creatorcontrib><creatorcontrib>Bouazzaoui, L.</creatorcontrib><creatorcontrib>Benchakroun, B.</creatorcontrib><creatorcontrib>Benbrahim, L.</creatorcontrib><creatorcontrib>Rostom, S.</creatorcontrib><creatorcontrib>Allali, F.</creatorcontrib><creatorcontrib>Bahiri, R.</creatorcontrib><creatorcontrib>Amine, B.</creatorcontrib><creatorcontrib>Benbouazza, K.</creatorcontrib><creatorcontrib>Hajjaj-Hassouni, N.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bouaddi, I.</au><au>Rkain, H.</au><au>Aktaou, S.</au><au>Raissouni, H.</au><au>Traki, L.</au><au>Bouazzaoui, L.</au><au>Benchakroun, B.</au><au>Benbrahim, L.</au><au>Rostom, S.</au><au>Allali, F.</au><au>Bahiri, R.</au><au>Amine, B.</au><au>Benbouazza, K.</au><au>Hajjaj-Hassouni, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0536 Tocilizumab offers clinical and ultrasonographic improvement in rheumatoid arthritis patients. Results of a 6 months follow-up study</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>71</volume><issue>Suppl 3</issue><spage>669</spage><epage>669</epage><pages>669-669</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Tocilizumab (TCZ) is a humanized anti-interleukin 6 (anti-IL 6) receptor antibody that has been demonstrated in previous clinical trials to improve rheumatoid arthritis (RA) and prevent radiographic progression. Musculoskeletal ultrasonography (MSUS) has increasingly been used as outcome measures in clinical trials of RA. Thus, we aimed to evaluate clinical and ultrasonographic (US) progression in RA patients treated with TCZ. Methods Twenty two consecutive patients, affected by RA [19 females, median age of 41 years (35,50), median disease duration of 72 months (36,171)] who were non-responders or partial responders to DMARDs therapy were commenced on Tocilizumab. The patients underwent clinical, laboratory, and assessment at baseline and after 6 months. The Disease Activity Score in 28 joints (DAS28) was recorded at inclusion and after a 6 months of therapy.The German ultrasound score included the following joints of the clinically dominant hand and foot: wrist, second and third metacarpophalangeal and proximal interphalangeal, and second and fifth metatarsophalangeal joints. Synovitis and synovial vascularity were scored semiquantitatively (grade 0–3) by gray-scale (GS) and power Doppler (PD) ultrasound. Clinical remission after 6 months of treatment was defined when DAS 28 was <2.6. Results At baseline, the median DAS28 score was 5.2 (4.4, 6.2) and the synovitis scores were 9.5 (6.7, 15) in GS ultrasound and 2.5 (0,7.2) in PD ultrasound. After 6 months of therapy, the DAS28 significantly decreased to 1.6 (0.8,2.4); p<0.001 and the GS and PD ultrasound scores significantly decreased to respectively 5 (4,6); p=0.001 and to 0.5 (0,1.7); p=0.04. Remission at 6 months was noted in 70% of patients. Conclusions This study indicates good evolution of RA patients under TCZ on basis on clinical and ultrasonographic findings. These results should be verified by further studies. Disclosure of Interest None Declared</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2012-eular.536</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.669-669 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_journals_1777973710 |
| source | BMJ Journals - NESLi2 |
| title | AB0536 Tocilizumab offers clinical and ultrasonographic improvement in rheumatoid arthritis patients. Results of a 6 months follow-up study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A09%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0536%E2%80%85Tocilizumab%20offers%20clinical%20and%20ultrasonographic%20improvement%20in%20rheumatoid%20arthritis%20patients.%20Results%20of%20a%206%20months%20follow-up%20study&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Bouaddi,%20I.&rft.date=2013-06&rft.volume=71&rft.issue=Suppl%203&rft.spage=669&rft.epage=669&rft.pages=669-669&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2012-eular.536&rft_dat=%3Cproquest_cross%3E4008650861%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777973710&rft_id=info:pmid/&rfr_iscdi=true |